Scleroderma (Systemic Sclerosis) – Current Treatment – Scleroderma (Systemic Sclerosis) | Treatment Algorithms: Claims Data Analysis | US | 2022
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis underlie a high mortality rate. This report covers the complex array of treatments used to treat the disease; ILD and skin fibrosis are targeted with systemic immunosuppressants, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, and off-label biologics. We provide needed context for emerging players seeking to capitalize on the unmet needs in this underserved population.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
- How has Boehringer Ingelheim’s Ofev been integrated into the treatment algorithm, and what is its source of business?
- What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SSc patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Boehringer Ingelheim, Roche, GlaxoSmithKline, Bayer HealthCare, AbbVie
Key drugs: Ofev, Esbriet, Rituxan and biosimilars, Adempas, calcium channel blockers, conventional oral immunosuppressants, corticosteroids, PDE-5 inhibitors, select biologics
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Scleroderma (Systemic Sclerosis) - Current Treatment - Scleroderma (Systemic Sclerosis) | Treatment Algorithms: Claims Data Analysis | US | 2022
- Treatment Algorithms CDA Scleroderma (Systemic Sclerosis) US | March 2022
- Treatment Algorithms CDA Scleroderma (Systemic Sclerosis) US 2022 Dashboard
Andrew Russell, Ph.D., is a business insights analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. In this role, he authors reports that distill the findings of his research into pharmaceutical markets related to autoimmune disease and bacterial infection. He worked previously in neurodegenerative disease research at Brigham and Women’s Hospital in Boston. He holds a Ph.D. in cellular and molecular biology from Brandeis University.